Article Correctness Is Author's Responsibility: Blood test can predict clinical response to immunotherapy in metastatic NSCLC

(University of Pennsylvania School of Medicine) Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.